1190 related articles for article (PubMed ID: 14972485)
21. Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies.
Catalona WJ; Carvalhal GF; Mager DE; Smith DS
J Urol; 1999 Aug; 162(2):433-8. PubMed ID: 10411052
[TBL] [Abstract][Full Text] [Related]
22. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
23. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
24. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
25. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
26. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
27. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
28. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
Jang TL; Han M; Roehl KA; Hawkins SA; Catalona WJ
Urology; 2006 Feb; 67(2):343-8. PubMed ID: 16442594
[TBL] [Abstract][Full Text] [Related]
29. Prospective detection of clinically relevant prostate cancer in the prostate specific antigen range 1 to 3 ng./ml. combined with free-to-total ratio 20% or less: the Aarau experience.
Recker F; Kwiatkowski MK; Huber A; Stamm B; Lehmann K; Tscholl R
J Urol; 2001 Sep; 166(3):851-5. PubMed ID: 11490232
[TBL] [Abstract][Full Text] [Related]
30. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
31. Age stratified functional outcomes after laparoscopic radical prostatectomy.
Rogers CG; Su LM; Link RE; Sullivan W; Wagner A; Pavlovich CP
J Urol; 2006 Dec; 176(6 Pt 1):2448-52. PubMed ID: 17085126
[TBL] [Abstract][Full Text] [Related]
32. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
33. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Sep; 64(3):516-21. PubMed ID: 15351582
[TBL] [Abstract][Full Text] [Related]
34. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
35. Clinical results of radical prostatectomy for patients with prostate cancer in Macau.
Ho SF; Lao HF; Li K; Tse MK
Chin Med J (Engl); 2008 Feb; 121(4):295-8. PubMed ID: 18304459
[TBL] [Abstract][Full Text] [Related]
36. Bladder neck preservation during radical retropubic prostatectomy and postoperative urinary continence.
Razi A; Yahyazadeh SR; Sedighi Gilani MA; Kazemeyni SM
Urol J; 2009; 6(1):23-6; discussion 26. PubMed ID: 19241337
[TBL] [Abstract][Full Text] [Related]
37. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate.
Walsh PC
J Urol; 2000 Jun; 163(6):1802-7. PubMed ID: 10799186
[TBL] [Abstract][Full Text] [Related]
38. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
39. Changes in continence and erectile function between 2 and 4 years after radical prostatectomy.
Glickman L; Godoy G; Lepor H
J Urol; 2009 Feb; 181(2):731-5. PubMed ID: 19091349
[TBL] [Abstract][Full Text] [Related]
40. Needle biopsy of recurrent adenocarcinoma of the prostate after radical prostatectomy.
Ripple MG; Potter SR; Partin AW; Epstein JI
Mod Pathol; 2000 May; 13(5):521-7. PubMed ID: 10824923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
